Post-marketing Clinical Safety Study of Xueshuantong forInjection (Lyophilized) by Centralized Hospital Monitoring

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-14005718

Enrollment

Unknown

Registered

2014-12-22

Start date

2015-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADR/ADE

Interventions

Treatment group:The administration of Xueshuantong for injection (Lyophilized)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients; 2. Patients who were administrated of Xueshuantong for injection (Lyophilized).

Exclusion criteria

Exclusion criteria: Patients who were not agree with the acquisition of the study required information.

Design outcomes

Primary

Measure	Time frame
ADR/ADE;	—

Countries

China

Contacts

Public ContactMingjun Zhu

zhumingjun317@163.com+86 13903846672

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026